CN114214422A - Kit, device and method for lung cancer diagnosis - Google Patents
Kit, device and method for lung cancer diagnosis Download PDFInfo
- Publication number
- CN114214422A CN114214422A CN202210144616.0A CN202210144616A CN114214422A CN 114214422 A CN114214422 A CN 114214422A CN 202210144616 A CN202210144616 A CN 202210144616A CN 114214422 A CN114214422 A CN 114214422A
- Authority
- CN
- China
- Prior art keywords
- mir
- nucleotide sequence
- sequence number
- sequence
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a kit, a device and a method for lung cancer diagnosis, wherein the kit comprises primers and probes for detecting a combination of long RNA markers of exosomes and miRNA markers, the long RNA markers comprise one or more of ARPC5, MBOAT2 and IL1B, and the miRNA markers comprise one or more of miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p. The noninvasive early lung cancer diagnosis method based on exosome has high sensitivity and high specificity in early lung cancer, and provides important value for early diagnosis of lung cancer. It is helpful for preventing and treating lung cancer in our country.
Description
The invention relates to a kit, a device and a method for diagnosing lung cancer, which are divided applications, wherein the application number of a parent application is 202111109658.2, the application date is 2020 and 05 and 11 days.
Technical Field
The invention relates to the field of medical diagnosis, in particular to a diagnostic kit, a device and a method for early lung cancer.
Background
Lung cancer is one of the main cancer species in China and even in the world. According to the latest global cancer statistics in 2018, the incidence and mortality of lung cancer are the first in all cancer species. According to the Chinese tumor registration data of 2019, 390.2 ten thousand cancer cases are newly added in 2015 of China, and the death cases of cancer are about 233.8 ten thousand, wherein lung cancer is the main cause of cancer death in China. Therefore, in order to improve the diagnosis and treatment behaviors of lung cancer in China and improve the prognosis of lung cancer patients, early diagnosis becomes an important problem for diagnosis and treatment of lung cancer.
With the application of low dose helical CT, more and more imaging is shown with lung nodules (single lesions <3cm in the lung interstitium and no associated atelectasis or lymphadenopathy) being discovered. However, not all lung nodules are malignant, and identification of benign and malignant lung nodules has been a difficult point in thoracic surgical clinical diagnosis and treatment. At present, noninvasive detection means such as plasma circulating tumor cells and circulating tumor free DNA are adopted, but the detection sensitivity in early lung cancer diagnosis is not high; therefore, there is a need to develop a highly sensitive method for noninvasive early detection of lung cancer.
Disclosure of Invention
The invention provides an exosome-based reagent, an exosome-based device and an exosome-based method for non-invasive early lung cancer diagnosis.
The invention provides a kit for lung cancer diagnosis, which comprises primers and probes for detecting a long RNA marker of an exosome and miRNA marker combination, wherein the long RNA marker comprises one or more of ARPC5, MBOAT2 and IL1B, and the miRNA marker comprises one or more of miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p.
Preferably, the marker is a combination of miR-450b-5p, let-7f-2-3p and ARPC 5.
Preferably, the marker is a combination of miR-106b-3P, miR-30e-5p and MBOAT 2.
Preferably, the marker is a combination of miR-106b-3P, miR-30e-5p, miR-3615, miR-885-5p and ARPC 5.
Preferably, the marker is a combination of miR-106b-3P, miR-125a-5p, miR-3615, miR-450b-5p and IL 1B. .
Preferably, the source of exosomes comprises one or more of blood, saliva and sputum.
Preferably, the primers and probes comprise:
primers and probes for detection of internal reference ACTB: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 1, the downstream primer is a nucleotide sequence shown as a sequence number 2, and the probe is a nucleotide sequence shown as a sequence number 3;
primers and probes for detection of ARPC 5: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 4, the downstream primer is a nucleotide sequence shown as a sequence number 5, and the probe is a nucleotide sequence shown as a sequence number 6;
primers and probes for detection of IL 1B: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 7, the downstream primer is a nucleotide sequence shown as a sequence number 8, and the probe is a nucleotide sequence shown as a sequence number 9;
primers and probes for detection of MBOAT 2: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 10, the downstream primer is a nucleotide sequence shown as a sequence number 11, and the probe is a nucleotide sequence shown as a sequence number 12;
reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 13, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 14, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 15;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 16, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 17, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 19, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 20, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 21;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 22, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 23, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 25, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 26, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 27;
reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 28, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 29, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 30;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 31, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 32, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 34, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 35, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 36;
reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 has a nucleotide sequence shown as sequence number 39, the PCR upstream primer has a nucleotide sequence shown as sequence number 37, the PCR downstream primer has a nucleotide sequence shown as sequence number 38, and the probe has a nucleotide sequence shown as sequence number 40.
In another aspect, the invention provides a device for lung cancer diagnosis, comprising primers and probes for detecting a combination of long RNA markers of exosomes, including one or more of ARPC5, MBOAT2, IL1B, and miRNA markers, including one or more of miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
In another aspect, the invention provides a method for lung cancer diagnosis comprising detecting the specificity of a combination of exosome long RNA markers comprising one or more of ARPC5, MBOAT2, IL1B and miRNA markers comprising one or more of miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
The invention provides a noninvasive early lung cancer diagnosis method based on exosome, which has high sensitivity and high specificity in early lung cancer and provides important value for early diagnosis of lung cancer. It is helpful for preventing and treating lung cancer in our country. Furthermore, the combination with the highest sensitivity can achieve the sensitivity of 100%, and the combination with the highest specificity can achieve the specificity of 96.67%, so that the combination has better performance.
Drawings
FIG. 1 is a ROC curve of the combination of miR-450b-5p + let-7f-2-3p + ARPC5 for detecting lung cancer.
FIG. 2 is a ROC curve of the combination of miR-106b-3P + miR-30e-5P + MBOAT2 for detecting lung cancer.
FIG. 3 is a ROC curve for the combination of miR-106b-3P + miR-30e-5P + miR-450b-5P + miR-885-5P + ARPC5 to detect lung cancer.
FIG. 4 is a ROC curve for the combination of miR-106b-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5 to detect lung cancer.
FIG. 5 is a ROC curve of the combination of miR-106b-3P + miR-30e-5P + miR-3615+ miR-885-5P + ARPC5 for detecting lung cancer.
FIG. 6 is a ROC curve of miR-106b-3P + miR-125a-5P + miR-3615+ miR-450b-5P + IL1B combination for detecting lung cancer.
Detailed Description
The Extracellular Vesicles (EVs; hereinafter Vesicles are referred to as Extracellular Vesicles) refer to vesicular bodies with a double-layer membrane structure, which are shed from cell membranes or secreted by cells, and have diameters of 30-1000nm, and mainly comprise MicroVesicles (MVs) and exosomes (exosomes), and the MicroVesicles are Vesicles shed from cell membranes after cells are activated or damaged. Extracellular vesicles are of great interest in disease diagnosis, particularly exosomes, due to their unique biological characteristics.
The exosome is a membrane vesicle with the particle size of 30-150 nm secreted into the extracellular environment after an intracellular multivesicular body and a cell membrane are fused, is an important medium for intercellular information transfer, and plays an important role in antigen presentation, apoptosis, inflammatory reaction, tumorigenesis development and metastasis processes. It is widely distributed in body fluid, including blood, saliva, urine, milk, hydrothorax and ascites, etc.; contains various inclusion substances such as DNA, RNA, protein and the like, and can be used as noninvasive diagnosis markers of various diseases such as tumors and the like. And miRNA is the most abundant nucleic acid component in exosome, so exosome miRNA has the potential of being used for early diagnosis of lung cancer.
According to the kit, the device and the method provided by the invention, the combination of long RNA and miRNA which show significant differential expression in exosome of a patient with early lung cancer is found through experimental research to be used as a marker for diagnosing early lung cancer.
In embodiments, the marker combination for diagnosing lung cancer comprises at least one long RNA and one miRNA. Wherein the long RNA comprises: ARPC5, MBOAT2, IL 1B. The MiRNA includes: miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p.
In some preferred embodiments, wherein the preferred combination is: miR-450b-5P + let-7f-2-3P + ARPC5, miR-106b-3P + miR-30e-5P + MBOAT2, miR-106b-3P + miR-30e-5P + miR-450b-5P + miR-885-5P + ARPC5miR-106b-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5, miR-106b-3P + miR-30e-5P + miR-3615+ miR-885P + ARPC5 and miR-106b-3P + miR-125a-5P + miR-3615+ miR-450b-5P + IL 1B. The combination can provide better basis for early diagnosis of lung cancer and indicate the risk of diseases.
In addition, the kit for lung cancer diagnosis of the present invention includes primers and probes for detecting the above exosome-long RNA marker. Primers and probes for detecting exosome markers include:
primers and probes for detection of internal reference ACTB: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 1, the downstream primer is specifically a nucleotide sequence shown as a sequence number 2, and the probe is specifically a nucleotide sequence shown as a sequence number 3;
primers and probes for detection of ARPC 5: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 4, the downstream primer is specifically a nucleotide sequence shown as a sequence number 5, and the probe is specifically a nucleotide sequence shown as a sequence number 6;
primers and probes for detection of IL 1B: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 7, the downstream primer is specifically a nucleotide sequence shown as a sequence number 8, and the probe is specifically a nucleotide sequence shown as a sequence number 9;
primers and probes for detection of MBOAT 2: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 10, the downstream primer is specifically a nucleotide sequence shown as a sequence number 11, and the probe is specifically a nucleotide sequence shown as a sequence number 12;
reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer is specifically a nucleotide sequence shown as a sequence number 13, the PCR upstream primer is specifically a nucleotide sequence shown as a sequence number 14, the downstream primer is specifically a nucleotide sequence shown as a sequence number 41, and the probe is specifically a nucleotide sequence shown as a sequence number 15;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 16, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 17, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer is specifically a nucleotide sequence shown as a sequence number 19, the PCR upstream primer is specifically a nucleotide sequence shown as a sequence number 20, the PCR downstream primer is specifically a nucleotide sequence shown as a sequence number 41, and the probe is specifically a nucleotide sequence shown as a sequence number 21;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 22, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 23, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 25, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 26, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 27;
reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 28, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 29, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 30;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 31, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 32, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown in a sequence number 34, the PCR upstream primer is specifically shown as a nucleotide sequence shown in a sequence number 35, the downstream primer is specifically shown as a nucleotide sequence shown in a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown in a sequence number 36;
reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 is specifically shown as a nucleotide sequence shown as a sequence number 39, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 37, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 38, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 40. The nucleotide sequences of the primers and probes are shown in Table 1.
TABLE 1
Further, the source of exosomes includes one or more of blood, saliva, and sputum.
The kit, the device and the method are suitable for individuals, such as people at high risk of lung cancer, normal individuals and patients after lung cancer operation.
The technical solution of the present invention will be described in detail with reference to the following embodiments, which are a part of the embodiments of the present invention, but not all of them. Other embodiments, which can be derived by one of ordinary skill in the art from the embodiments of the present invention without creative efforts, are within the protection scope of the present invention.
In order to screen an exosome marker related to diagnosis of colon lung cancer, 50 cases of early lung cancer patients and 72 cases of controls respectively take blood of not less than 10ml and separate plasma, the blood is used for separating exosomes in the plasma by a classical ultracentrifugation method and extracting RNA, and the obtained RNA is respectively subjected to RNA library construction and sequencing. The data obtained were analyzed bioinformatically to compare differentially expressed RNA in early lung cancer patients and controls. These exosome-derived RNA-level markers can be used for early diagnosis of lung cancer.
Further directed to the method wherein the RNA marker is further analyzed by the following steps: (1) collecting body fluid samples (including blood, sputum and saliva) of individuals to be detected; (2) isolating exosomes in the body fluid; (3) detecting the expression level of target RNA by using a two-step method; (4) normalizing the expression level of the detection target RNA by using the reference gene; (5) substituting the normalized gene expression level into a judgment model to obtain an output value; (6) and judging whether the individual to be detected is lung cancer or not according to the output value of the model and the judgment threshold value.
The kit comprises a PCR primer, a probe and a standard substance for detecting the long RNA marker of the exosome and a two-step detection system of PCR.
The invention comprises selecting internal reference beta-Actin (ACTB) to carry out the quantification of long RNA, and taking U6 as the internal reference to carry out the quantification of miRNA. Wherein the expression level of the marker is calculated by using a quantitative formula 2 delta Ct according to the detection Ct value by using the quantification of the target RNA when the reference is selected. Having obtained the target RNA expression level, the ROC characteristic curve and AUC were used to assess the accuracy of lung cancer detection by single RNA or by combining multiple RNAs.
Example 1 screening of exosome mRNA and LncRNA markers associated with early lung cancer based on high throughput sequencing
In order to screen an exosome marker related to early lung cancer diagnosis, 50 cases of patients 72 and controls for early lung cancer diagnosis are respectively selected, blood is taken to be not less than 10ml, plasma is separated, exosome in the plasma is separated by a classical ultracentrifugation method, RNA is extracted by a qiagen miRNeasy mini kit, and the obtained RNA is subjected to micro-enucleation ribosome strand specific RNA library-building sequencing and small RNA library-building sequencing. The obtained data were analyzed by bioinformatics, and long RNAs and mirnas differentially expressed in early lung cancer patients and controls were compared to obtain long RNAs with significant differences as shown in table 2 below. These exosome-derived RNA-level markers can be used for early diagnosis of lung cancer.
TABLE 2
| RNA type | ID | Pvalue | log2FC | regulated |
| mRNA | MBOAT2 | 4.23E-05 | 1.023772461 | up |
| mRNA | IL1B | 0.000162055 | 1.050636789 | up |
| mRNA | ARPC5 | 0.000871259 | 1.066858402 | up |
| miRNA | hsa-let-7f-2-3p | 0.00027664 | -0.446890593 | down |
| miRNA | hsa-miR-450b-5p | 0.000293888 | -0.402238286 | down |
| miRNA | hsa-miR-106b-3p | 0.001429894 | 0.189007463 | up |
| miRNA | hsa-miR-885-5p | 0.001455856 | -0.589409694 | down |
| miRNA | hsa-miR-30e-5p | 0.001592304 | -0.329476279 | down |
| miRNA | hsa-miR-3615 | 0.00283095 | 0.419677035 | up |
| miRNA | hsa-miR-4746-5p | 0.003524579 | 0.315578167 | up |
| miRNA | hsa-miR-125a-5p | 0.004298578 | -0.492462437 | down |
Example 2 fluorescent quantitation PCR platform based miRNA detection system
1. miRNA reverse transcription reaction system
miRNA reverse transcription reagents, enzymes and oligdT were purchased from TAKARA, standards were synthesized from Shanghai Yinxie substrate, and primers with reversed specificity were synthesized by Suzhou Hongyu. A20 ul reverse transcription system was used, as shown in Table 3 below.
TABLE 3
2. PCR reaction system
The PCR reaction mixture was purchased from TAKARA, the upstream primer, the probe, i.e., the universal downstream primer, was synthesized by Honghong, Suzhou, and the fluorescent quantitative PCR instrument was ABI 7500. The PCR reaction system is shown in Table 4 below:
TABLE 4
The PCR procedure was 95 ℃ for 10min, (95 ℃ for 15s, 55 ℃ for 30s) for 15 cycles without fluorescence collection, and (95 ℃ for 15s, 55 ℃ for 30s) for 35 cycles with fluorescence collection.
Example 3 fluorescent quantitation-based PCR platform mRNA and LncRNA detection system
1. Reverse transcription of mRNA and LncRNA
PrimeScript from takara was usedTMRT reagent Kit (Perfect Real Time) and Premix Ex TaqTM(Probe qPCR) kit for reverse transcription and qPCR detection.
Preparing a reverse transcription reaction system (reaction liquid is prepared on ice), then putting the reaction system into a PCR instrument for reaction under the reaction conditions of 37 ℃ for 60min, 85 ℃ for 5s and 12 ℃ for infinity, and adding 50ul DEPC-H after the reverse transcription is finished2Diluting with O, taking 3ul as a template, and carrying out PCR reaction. The reverse transcription reaction system is shown in Table 5 below.
TABLE 5
2. mRNA and LncRNA qPCR
The qPCR reaction system was prepared as follows (reaction solution was prepared on ice) and a no template control was set as a negative control. Then, the mixture was put into a real-time fluorescence PCR apparatus (ABI7500) to perform amplification detection under the following reaction conditions. The qPCR reaction system is shown in table 6 below and the qPCR reaction conditions are shown in table 7 below.
TABLE 6
TABLE 7
Example 4 evaluation of Effect of Single-marker Lung cancer early diagnosis detection
1. Sample collection
10ml of blood of control samples of early stage (stage I and stage II) lung nodule lung cancer patients, benign lung nodule patients, healthy persons, etc. diagnosed in hospitals were collected and separated into plasma.
2. Exosome RNA extraction
Plasma exosome separation is carried out by ultracentrifugation or Exosuurur of Echobiotech (Beijing Enzekangtai), long RNA in exosome is extracted from the separated exosome by a Qiagen MiReasy mini kit, RNA concentration and quality are detected by Agilent2100, and the RNA concentration is recorded.
3. RNA two-step detection system
A two-step method detection system based on mRNA of a PCR platform in example 1 is adopted to detect plasma exosome mRNA and LncRNA of 30 patients with early lung cancer and 30 control samples (healthy people and benign nodules), the Ct value of target long RNA is detected, and the relative expression amount is calculated according to the Ct value and a relative quantitative formula.
4. Evaluation of exosome RNA single marker diagnosis early lung cancer performance
As shown in the following table, the Ct values of the target genes were detected for plasma exosomes of 30 and 30 control samples (healthy and benign lesions) of early stage lung cancer patients, wherein the long RNA was referenced to the internal reference β -Actin, and the miRNA was referenced to the internal reference U6; and obtaining the relative expression level of the RNA according to the Ct value. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And performing statistical analysis on the detection result by adopting an R language. The performance evaluation of the single marker is shown in the following table 8, wherein miR-450b-5p and miR-3615 have good sensitivity, and let-7f-2-3p has good specificity.
TABLE 8
Example 5 evaluation of Long RNA and miRNA in combination for early diagnosis of Lung cancer
1. Three marker combination performance evaluation
Relative expression levels of each long RNA were calculated according to the method described in example 3, and the three marker combinations were trained using logistic regression, and the combinations with AUC of 0.76 or higher for the three marker combinations were obtained as shown in table 9 below. The miR-450b-5p + let-7f-2-3p + ARPC5 combination has the optimal performance, the accuracy is 76.67%, and the AUC curves are respectively shown in figure 1; the miR-106b-3P + miR-30e-5P + MBOAT2 has better specificity (80%), and the AUC curve is shown in the following figure 1.
TABLE 9
2. Five marker combination performance evaluation
Relative expression levels of each long RNA were calculated according to the method described in example 3, and five marker combinations were trained using logistic regression, and the combinations having AUC of 0.85 or more of the five marker combinations were obtained as shown in table 10 below. Wherein two combinations of miR-106b-3P + miR-30e-5P + miR-450b-5P + miR-885-5P + ARPC5 and miR-106b-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5 have good sensitivity which is 93.33% and 100% respectively, and AUC curves are shown in figure 3 and figure 4; the miR-106b-3P + miR-30e-5P + miR-3615+ miR-885-5P + ARPC5 and miR-106b-3P + miR-125a-5P + miR-3615+ miR-450b-5P + IL1B have good specificity of 90% and 96.67% respectively, and AUC curves are shown in figure 5 and figure 6.
The data show that the exosome-based noninvasive early lung cancer diagnosis method has high sensitivity and high specificity in early lung cancer, and provides important value for early diagnosis of lung cancer. It is helpful for preventing and treating lung cancer in our country. The combination with the highest sensitivity can achieve the sensitivity of 100%, and the combination with the highest specificity can achieve the specificity of 96.67%, so that the method has better performance.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Sequence listing
<110> tumor hospital of Chinese medical science institute
<120> kit, device and method for lung cancer diagnosis
<130> 2000003
<160> 41
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
cctcgccttt gccgatcc 18
<210> 2
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
catgcccacc atcacgc 17
<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
acccgccgcc agctcacca 19
<210> 4
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
cgaggtggac tcctgcct 18
<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ctgcccggtc cttcactg 18
<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
actcttggtg ttgatagggg ggttc 25
<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gccctaaaca gatgaagtgc tc 22
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
tctgccctct ggatggcggc at 22
<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
tctgctgatt tttcaggccc a 21
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
<210> 12
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
tggcttgcga aattcatgat gggatgt 27
<210> 13
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacggaaag 50
<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
agcgcctata cagtctactg t 21
<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
tcgcactgga tacgacggaa agac 24
<210> 16
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcagca 50
<210> 17
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
accgcactgt gggtact 17
<210> 18
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
tcgcactgga tacgacgcag ca 22
<210> 19
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcacag 50
<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
tcgcactgga tacgactcac aggt 24
<210> 22
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccttcca 50
<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
accgctgtaa acatccttga c 21
<210> 24
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
tcgcactgga tacgaccttc ca 22
<210> 25
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgagccg 50
<210> 26
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
cctctctcgg ctcctcg 17
<210> 27
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
tcgcactgga tacgacgagc cg 22
<210> 28
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattca 50
<210> 29
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 29
tccgcttttg caatatgttc c 21
<210> 30
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
ttcgcactgg atacgactat tcagga 26
<210> 31
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 31
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctgca 50
<210> 32
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 32
ccggtcccag gagaacc 17
<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 33
tcgcactgga tacgactctg ca 22
<210> 34
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 34
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagaggc 50
<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 35
<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 36
tcgcactgga tacgacagag gc 22
<210> 37
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 37
ctcgcttcgg cagcaca 17
<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 38
<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 39
<210> 40
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 40
agaagattag catggcccct gcgca 25
<210> 41
<211> 16
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 41
gtgcagggtc cgaggt 16
Claims (4)
1. The application of primers and probes for detecting exosome long RNA markers and miRNA markers in preparation of lung cancer diagnostic kits is characterized in that the markers are a combination of miR-106b-3P, miR-30e-5p, miR-4746-5p, miR-885-5p and ARPC 5.
2. The use according to claim 1, wherein the source of exosomes comprises one or more of blood, saliva and sputum.
3. The use of claim 1, wherein the primers and probes comprise:
primers and probes for detection of ARPC 5: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 4, the downstream primer is a nucleotide sequence shown as a sequence number 5, and the probe is a nucleotide sequence shown as a sequence number 6;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 16, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 17, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 22, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 23, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 31, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 32, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 34, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 35, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 36.
4. The application of primers and probes for detecting exosome long RNA markers and miRNA markers in preparation of a lung cancer diagnosis device is characterized in that the markers are a combination of miR-106b-3P, miR-30e-5p, miR-4746-5p, miR-885-5p and ARPC 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210144616.0A CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010262401 | 2020-03-30 | ||
| CN202010262401X | 2020-03-30 | ||
| CN202010391533.2A CN111455057B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144616.0A CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010391533.2A Division CN111455057B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114214422A true CN114214422A (en) | 2022-03-22 |
| CN114214422B CN114214422B (en) | 2023-06-27 |
Family
ID=71674744
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109658.2A Active CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144431.XA Active CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144442.8A Active CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202210144440.9A Active CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202111108621.8A Active CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
| CN202210144616.0A Active CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202111109657.8A Active CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202010391533.2A Active CN111455057B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144425.4A Active CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202210144490.7A Active CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144702.1A Active CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109658.2A Active CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144431.XA Active CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144442.8A Active CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202210144440.9A Active CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202111108621.8A Active CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109657.8A Active CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202010391533.2A Active CN111455057B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144425.4A Active CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202210144490.7A Active CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144702.1A Active CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (11) | CN113774138B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725632A (en) * | 2009-08-28 | 2012-10-10 | 奥斯瑞根公司 | MiRNA biomarkers of lung disease |
| CN104411339A (en) * | 2012-06-21 | 2015-03-11 | 北京命码生科科技有限公司 | Microparticle comprising functional microRNA/siRNA and application thereof |
| CN106471132A (en) * | 2014-06-18 | 2017-03-01 | 东丽株式会社 | The detection kit of pulmonary carcinoma or device and detection method |
| US20190192691A1 (en) * | 2016-04-11 | 2019-06-27 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502115A (en) * | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | Diagnostic method for small cell lung cancer |
| US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| CN101475984A (en) * | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | Non-small cell lung cancer detection marker, detection method thereof, related biochip and reagent kit |
| CN102272330B (en) * | 2009-02-23 | 2014-04-23 | 博奥生物有限公司 | Kit for diagnosing lung cancer, determining prognosis, and improving patient survival |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| AU2012220872A1 (en) * | 2011-02-22 | 2013-09-12 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers |
| EP2681336A4 (en) * | 2011-03-02 | 2014-11-19 | Groove Biopharma Corp | Enhanced biodistribution of oligomers |
| US20140243403A1 (en) * | 2011-06-03 | 2014-08-28 | The General Hospital Corporation | Treating colorectal, pancreatic, and lung cancer |
| CN103651811A (en) * | 2012-09-07 | 2014-03-26 | 北京命码生科科技有限公司 | Human milk micro ribonucleic acids and application thereof |
| JP6144355B2 (en) * | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | Chemically modified mRNA |
| EP2964234A4 (en) * | 2013-03-09 | 2016-12-07 | Moderna Therapeutics Inc | Heterologous untranslated regions for mrna |
| AU2014254091B2 (en) * | 2013-04-15 | 2019-03-21 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
| CN103484550B (en) * | 2013-09-30 | 2014-09-10 | 中国科学院上海微系统与信息技术研究所 | MicroRNA biological markers for early lung cancer diagnosis and application thereof |
| US20160237496A1 (en) * | 2013-10-02 | 2016-08-18 | Hitachichemical Company Ltd. | Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens |
| WO2016011068A1 (en) * | 2014-07-14 | 2016-01-21 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| EP3347493B1 (en) * | 2015-09-08 | 2022-03-30 | The Translational Genomics Research Institute | Biomarkers and methods of diagnosing mild traumatic brain injuries |
| CN105675774B (en) * | 2016-01-19 | 2018-10-23 | 上海交通大学 | The preparation method of saliva excretion body and its application in molecule diagnosis |
| EP3571212B1 (en) * | 2017-01-23 | 2024-03-06 | Trustees of Boston University | Methods relating to lung cancer |
| CN106755544A (en) * | 2017-03-10 | 2017-05-31 | 大连医科大学附属第医院 | MiRNA marker and application in a kind of serum excretion body related to adenocarcinoma of lung early diagnosis |
| CN110452981A (en) * | 2017-06-07 | 2019-11-15 | 深圳市海普洛斯生物科技有限公司 | The kit of early screening of lung cancer based on peripheral blood |
| US11359247B2 (en) * | 2017-07-31 | 2022-06-14 | Massachusetts Institute Of Technology | High performance multi-input microRNA sensors and uses thereof |
| CN113930503B (en) * | 2017-08-14 | 2024-01-23 | 江苏为真生物医药技术股份有限公司 | Application of miR-126 and miR-152 combination in preparation of reagent or kit for diagnosing and indicating lung cancer |
| EP3763826A4 (en) * | 2018-02-22 | 2021-06-30 | Osaka University | Analysis/diagnosis method utilizing rna modification |
| CN110872628A (en) * | 2018-08-30 | 2020-03-10 | 杨昆德 | Use of extracellular vesicles as biomarkers for the preparation of kits |
| CN108998530B (en) * | 2018-08-31 | 2021-10-08 | 昆明医科大学第一附属医院 | Lung cancer up-regulated long-chain non-coding RNA marker and application thereof |
| CN109971853A (en) * | 2019-03-14 | 2019-07-05 | 中国科学院北京基因组研究所 | One kind molecular marker relevant to Diagnosis of Non-Small Cell Lung and its application |
| CN110699457B (en) * | 2019-10-30 | 2022-11-25 | 深圳瑞科生物科技有限公司 | Primer group and kit for detecting lung cancer |
| CN115261465A (en) * | 2020-03-30 | 2022-11-01 | 中国医学科学院肿瘤医院 | Application of exosome miR-125a-5p, miR-3158-3p and the like in lung cancer diagnosis |
| CN114231633B (en) * | 2020-03-30 | 2022-05-20 | 中国医学科学院肿瘤医院 | Application of exosomes ARPC5, STK3 and the like in lung cancer diagnosis |
| CN111676291B (en) * | 2020-07-14 | 2021-04-13 | 徐州医科大学 | miRNA marker for lung cancer risk assessment |
-
2020
- 2020-05-11 CN CN202111109658.2A patent/CN113774138B/en active Active
- 2020-05-11 CN CN202210144431.XA patent/CN114214420B/en active Active
- 2020-05-11 CN CN202210144442.8A patent/CN114231638B/en active Active
- 2020-05-11 CN CN202210144440.9A patent/CN114214421B/en active Active
- 2020-05-11 CN CN202111108621.8A patent/CN113930505B/en active Active
- 2020-05-11 CN CN202210144616.0A patent/CN114214422B/en active Active
- 2020-05-11 CN CN202111109657.8A patent/CN113801936B/en active Active
- 2020-05-11 CN CN202010391533.2A patent/CN111455057B/en active Active
- 2020-05-11 CN CN202210144425.4A patent/CN114214419B/en active Active
- 2020-05-11 CN CN202210144490.7A patent/CN114410794B/en active Active
- 2020-05-11 CN CN202210144702.1A patent/CN114214423B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725632A (en) * | 2009-08-28 | 2012-10-10 | 奥斯瑞根公司 | MiRNA biomarkers of lung disease |
| CN104411339A (en) * | 2012-06-21 | 2015-03-11 | 北京命码生科科技有限公司 | Microparticle comprising functional microRNA/siRNA and application thereof |
| CN106471132A (en) * | 2014-06-18 | 2017-03-01 | 东丽株式会社 | The detection kit of pulmonary carcinoma or device and detection method |
| US20190192691A1 (en) * | 2016-04-11 | 2019-06-27 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
Non-Patent Citations (2)
| Title |
|---|
| VALERIO DEL VESCOVO ET AL.: "MicroRNAs as lung cancer biomarkers", WORLD JOURNAL OF CLINICAL ONCOLOGY, vol. 5, no. 4, pages 604 - 620, XP093024741, DOI: 10.5306/wjco.v5.i4.604 * |
| 徐亚妮 等: "长链非编码RNA TUG1和微小RNA-132 在非小细胞肺癌中的表达及意义", 江苏医药, vol. 46, no. 2, pages 182 - 186 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114214422B (en) | 2023-06-27 |
| CN114410794A (en) | 2022-04-29 |
| CN114231638B (en) | 2023-06-27 |
| CN113774138A (en) | 2021-12-10 |
| CN113801936B (en) | 2022-04-19 |
| CN114214419A (en) | 2022-03-22 |
| CN114410794B (en) | 2023-06-23 |
| CN114214420B (en) | 2023-06-23 |
| CN114214421B (en) | 2023-06-23 |
| CN114214421A (en) | 2022-03-22 |
| CN111455057B (en) | 2021-10-26 |
| CN111455057A (en) | 2020-07-28 |
| CN114214423A (en) | 2022-03-22 |
| CN113774138B (en) | 2022-03-18 |
| CN114231638A (en) | 2022-03-25 |
| CN114214419B (en) | 2023-06-27 |
| CN113930505B (en) | 2022-04-19 |
| CN114214420A (en) | 2022-03-22 |
| CN114214423B (en) | 2023-06-27 |
| CN113801936A (en) | 2021-12-17 |
| CN113930505A (en) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113621708B (en) | Kit, device and method for lung cancer diagnosis | |
| CN114150066B (en) | Application of exosomes CDA, HMGN1 and the like in lung cancer diagnosis | |
| CN113930505B (en) | Kit and device for lung cancer diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |